---
document_datetime: 2025-12-02 04:53:42
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/gavreto.html
document_name: gavreto.html
version: success
processing_time: 0.0831924
conversion_datetime: 2025-12-24 04:23:01.536048
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Gavreto

[RSS](/en/individual-human-medicine.xml/67481)

##### Withdrawn

This medicine's authorisation has been withdrawn

pralsetinib Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Gavreto](#news-on)
- [More information on Gavreto](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 24 October 2024, the European Commission withdrew the marketing authorisation for Gavreto (pralsetinib) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Blueprint Medicines (Netherlands) B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Gavreto was granted a conditional marketing authorisation in the EU on 18 November 2021 for the treatment of non-small cell lung cancer (NSCLC).

The European Public Assessment Report (EPAR) for Gavreto is updated to indicate that the marketing authorisation is no longer valid.

Gavreto : EPAR - Medicine Overview

Reference Number: EMA/576914/2021

English (EN) (236 KB - PDF)

**First published:** 09/12/2021

**Last updated:** 17/01/2025

[View](/en/documents/overview/gavreto-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-610)

български (BG) (249.82 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/bg/documents/overview/gavreto-epar-medicine-overview_bg.pdf)

español (ES) (193.34 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/es/documents/overview/gavreto-epar-medicine-overview_es.pdf)

čeština (CS) (231.06 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/cs/documents/overview/gavreto-epar-medicine-overview_cs.pdf)

dansk (DA) (186.78 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/da/documents/overview/gavreto-epar-medicine-overview_da.pdf)

Deutsch (DE) (199 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/de/documents/overview/gavreto-epar-medicine-overview_de.pdf)

eesti keel (ET) (170.51 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/et/documents/overview/gavreto-epar-medicine-overview_et.pdf)

ελληνικά (EL) (256.48 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/el/documents/overview/gavreto-epar-medicine-overview_el.pdf)

français (FR) (197.29 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/fr/documents/overview/gavreto-epar-medicine-overview_fr.pdf)

hrvatski (HR) (222.31 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/hr/documents/overview/gavreto-epar-medicine-overview_hr.pdf)

italiano (IT) (185.24 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/it/documents/overview/gavreto-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (234.46 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/lv/documents/overview/gavreto-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (225.85 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/lt/documents/overview/gavreto-epar-medicine-overview_lt.pdf)

magyar (HU) (226.16 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/hu/documents/overview/gavreto-epar-medicine-overview_hu.pdf)

Malti (MT) (234.25 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/mt/documents/overview/gavreto-epar-medicine-overview_mt.pdf)

Nederlands (NL) (195.16 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/nl/documents/overview/gavreto-epar-medicine-overview_nl.pdf)

polski (PL) (229.22 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/pl/documents/overview/gavreto-epar-medicine-overview_pl.pdf)

português (PT) (193.14 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/pt/documents/overview/gavreto-epar-medicine-overview_pt.pdf)

română (RO) (227.17 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/ro/documents/overview/gavreto-epar-medicine-overview_ro.pdf)

slovenčina (SK) (225.98 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/sk/documents/overview/gavreto-epar-medicine-overview_sk.pdf)

slovenščina (SL) (218.09 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/sl/documents/overview/gavreto-epar-medicine-overview_sl.pdf)

Suomi (FI) (182.23 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/fi/documents/overview/gavreto-epar-medicine-overview_fi.pdf)

svenska (SV) (184.88 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/sv/documents/overview/gavreto-epar-medicine-overview_sv.pdf)

Gavreto : EPAR - Risk management plan

English (EN) (2.45 MB - PDF)

**First published:** 09/12/2021

**Last updated:** 17/01/2025

[View](/en/documents/rmp/gavreto-epar-risk-management-plan_en.pdf)

## Product information

Gavreto : EPAR - Product Information

English (EN) (1.4 MB - PDF)

**First published:** 09/12/2021

**Last updated:** 17/01/2025

[View](/en/documents/product-information/gavreto-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-670)

български (BG) (2.1 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/bg/documents/product-information/gavreto-epar-product-information_bg.pdf)

español (ES) (1.53 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/es/documents/product-information/gavreto-epar-product-information_es.pdf)

čeština (CS) (1.72 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/cs/documents/product-information/gavreto-epar-product-information_cs.pdf)

dansk (DA) (1.48 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/da/documents/product-information/gavreto-epar-product-information_da.pdf)

Deutsch (DE) (1.58 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/de/documents/product-information/gavreto-epar-product-information_de.pdf)

eesti keel (ET) (1.49 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/et/documents/product-information/gavreto-epar-product-information_et.pdf)

ελληνικά (EL) (2.22 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/el/documents/product-information/gavreto-epar-product-information_el.pdf)

français (FR) (1.64 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/fr/documents/product-information/gavreto-epar-product-information_fr.pdf)

hrvatski (HR) (1.81 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/hr/documents/product-information/gavreto-epar-product-information_hr.pdf)

íslenska (IS) (1.48 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/is/documents/product-information/gavreto-epar-product-information_is.pdf)

italiano (IT) (1.55 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/it/documents/product-information/gavreto-epar-product-information_it.pdf)

latviešu valoda (LV) (1.91 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/lv/documents/product-information/gavreto-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.94 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/lt/documents/product-information/gavreto-epar-product-information_lt.pdf)

magyar (HU) (1.9 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/hu/documents/product-information/gavreto-epar-product-information_hu.pdf)

Malti (MT) (1.94 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/mt/documents/product-information/gavreto-epar-product-information_mt.pdf)

Nederlands (NL) (1.35 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/nl/documents/product-information/gavreto-epar-product-information_nl.pdf)

norsk (NO) (1.46 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/no/documents/product-information/gavreto-epar-product-information_no.pdf)

polski (PL) (1.86 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/pl/documents/product-information/gavreto-epar-product-information_pl.pdf)

português (PT) (1.43 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/pt/documents/product-information/gavreto-epar-product-information_pt.pdf)

română (RO) (1.91 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/ro/documents/product-information/gavreto-epar-product-information_ro.pdf)

slovenčina (SK) (1.8 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/sk/documents/product-information/gavreto-epar-product-information_sk.pdf)

slovenščina (SL) (1.73 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/sl/documents/product-information/gavreto-epar-product-information_sl.pdf)

Suomi (FI) (1.53 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/fi/documents/product-information/gavreto-epar-product-information_fi.pdf)

svenska (SV) (1.42 MB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/sv/documents/product-information/gavreto-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** T/0021 17/07/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Gavreto : EPAR - All authorised presentations

English (EN) (47.08 KB - PDF)

**First published:** 09/12/2021

**Last updated:** 17/01/2025

[View](/en/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-870)

български (BG) (76.12 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/bg/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_bg.pdf)

español (ES) (54.98 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/es/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_es.pdf)

čeština (CS) (67.16 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/cs/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (55.66 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/da/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (50.81 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/de/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (42.8 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/et/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (75.33 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/el/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_el.pdf)

français (FR) (55.75 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/fr/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (67.35 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/hr/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (49.46 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/is/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_is.pdf)

italiano (IT) (60.61 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/it/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (68.18 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/lv/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (71.81 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/lt/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (67.14 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/hu/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (69.63 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/mt/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (49.28 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/nl/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (53.45 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/no/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_no.pdf)

polski (PL) (77.24 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/pl/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_pl.pdf)

português (PT) (52.92 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/pt/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_pt.pdf)

română (RO) (72.99 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/ro/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (69.71 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/sk/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (57.72 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/sl/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (48.23 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/fi/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (42.93 KB - PDF)

**First published:**

09/12/2021

**Last updated:**

17/01/2025

[View](/sv/documents/all-authorised-presentations/gavreto-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Gavreto Active substance pralsetinib International non-proprietary name (INN) or common name pralsetinib Therapeutic area (MeSH) Carcinoma, Non-Small-Cell Lung Anatomical therapeutic chemical (ATC) code L01EX23

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.

## Authorisation details

EMA product number EMEA/H/C/005413

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Marketing authorisation holder

Blueprint Medicines (Netherlands) B.V.

Gustav Mahlerplein 2 1082MA Amsterdam Netherlands

Opinion adopted 16/09/2021 Marketing authorisation issued 18/11/2021 Withdrawal of marketing authorisation 24/10/2024 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Gavreto : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (449.59 KB - PDF)

**First published:** 13/12/2021

**Last updated:** 17/01/2025

[View](/en/documents/procedural-steps-after/gavreto-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Gavreto : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/41191/2021

English (EN) (11.52 MB - PDF)

**First published:** 09/12/2021

**Last updated:** 17/01/2025

[View](/en/documents/assessment-report/gavreto-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Gavreto

Adopted

Reference Number: Gavreto

English (EN) (178.35 KB - PDF)

**First published:** 17/09/2021

**Last updated:** 17/01/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-gavreto_en.pdf)

#### News on Gavreto

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-november-2022) 11/11/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-september-2021) 17/09/2021

#### More information on Gavreto

- [EMEA-002575-PIP02-20 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002575-pip02-20)
- [Gavreto - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/gavreto)
- [EMEA-002575-PIP03-21 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002575-pip03-21)
- [Gavreto - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/gavreto)

**This page was last updated on** 17/01/2025

## Share this page

[Back to top](#main-content)